rs779834376
Variant summary
Our verdict is Likely pathogenic. The variant received 6 ACMG points: 6P and 0B. PM5PP3_Strong
The NM_058216.3(RAD51C):c.935G>A(p.Arg312Gln) variant causes a missense change. The variant allele was found at a frequency of 0.0000223 in 1,613,030 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R312G) has been classified as Likely pathogenic.
Frequency
Consequence
NM_058216.3 missense
Scores
Clinical Significance
Conservation
Publications
- breast-ovarian cancer, familial, susceptibility to, 3Inheritance: AD Classification: STRONG, LIMITED Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics
- Fanconi anemia complementation group OInheritance: AR Classification: STRONG, MODERATE, LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics, ClinGen
- hereditary breast ovarian cancer syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 6 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 151992Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000239 AC: 6AN: 251358 AF XY: 0.0000368 show subpopulations
GnomAD4 exome AF: 0.0000240 AC: 35AN: 1461038Hom.: 0 Cov.: 30 AF XY: 0.0000261 AC XY: 19AN XY: 726870 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000658 AC: 1AN: 151992Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74220 show subpopulations
ClinVar
Submissions by phenotype
Fanconi anemia complementation group O Pathogenic:1Uncertain:2
This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 312 of the RAD51C protein (p.Arg312Gln). This variant is present in population databases (rs779834376, gnomAD 0.006%). This missense change has been observed in individual(s) with Fanconi anemia (PMID: 29278735). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 229887). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt RAD51C protein function with a negative predictive value of 80%. Studies have shown that this missense change is associated with inconclusive levels of altered splicing (internal data). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. -
PS4, PM3 -
- -
Hereditary cancer-predisposing syndrome Uncertain:3
- -
This missense variant replaces arginine with glutamine at codon 312 of the RAD51C protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual having clinical features of Fanconi anemia in compound heterozygosity with a splice site variant c.571+5G>A (PMID: 2927873). In a breast cancer case-control study, this variant has been reported in 1/60466 cases and 1/53461 unaffected controls (OR=0.884; 95%CI 0.055 to 14.136; p-value=1; Leiden Open Variation Database DB-ID RAD51C_000200) (PMID: 33471991). This variant has been identified in 6/251358 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
The p.R312Q variant (also known as c.935G>A), located in coding exon 7 of the RAD51C gene, results from a G to A substitution at nucleotide position 935. The arginine at codon 312 is replaced by glutamine, an amino acid with highly similar properties. This variant has been reported in conjunction with another variant in RAD51C in an individual diagnosed with clinical features of Fanconi anemia (Jacquinet A et al. Eur J Med Genet, 2018 May;61:257-261). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. -
not provided Uncertain:1
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 27535533, 14704354, 29278735) -
Familial ovarian cancer Uncertain:1
- -
Hereditary breast ovarian cancer syndrome Uncertain:1
According to the ACMG SVI adaptation criteria we chose these criteria: PM3 (medium pathogenic): ClinVar Eintrag: This missense change has been observed in individual(s) with Fanconi anemia (PMID: 29278735). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. , PM5 (medium pathogenic): RAD51C c.934C>T p.R312W =LP -
Breast-ovarian cancer, familial, susceptibility to, 3 Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at